APA (7th ed.) Citation

Ngaimisi, E., Minzi, O., Mugusi, S., Sasi, P., Riedel, K., Suda, A., . . . Diczfalusy, U. (2014). Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4[beta]-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. Journal of Antimicrobial Chemotherapy (JAC), 69(12), 3311. https://doi.org/10.1093/jac/dku286

Chicago Style (17th ed.) Citation

Ngaimisi, E., et al. "Pharmacokinetic and Pharmacogenomic Modelling of the CYP3A Activity Marker 4[beta]-hydroxycholesterol During Efavirenz Treatment and Efavirenz/rifampicin Co-treatment." Journal of Antimicrobial Chemotherapy (JAC) 69, no. 12 (2014): 3311. https://doi.org/10.1093/jac/dku286.

MLA (9th ed.) Citation

Ngaimisi, E., et al. "Pharmacokinetic and Pharmacogenomic Modelling of the CYP3A Activity Marker 4[beta]-hydroxycholesterol During Efavirenz Treatment and Efavirenz/rifampicin Co-treatment." Journal of Antimicrobial Chemotherapy (JAC), vol. 69, no. 12, 2014, p. 3311, https://doi.org/10.1093/jac/dku286.